Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Viracta Therapeutics Reported Phase 2 NAVAL-1 Trial Results From Stages 1 And 2 Of The Relapsed Or Refractory Epstein-Barr Virus-Positive Peripheral T-cell Lymphoma Cohort

Author: Benzinga Newsdesk | August 14, 2024 07:09am

 Additionally, the Company received productive feedback from its meeting with the U.S. Food and Drug Administration (FDA), providing clarity on the potential regulatory path to initial registration of Nana-val in patients with R/R EBV+ PTCL. Based on FDA's feedback, Viracta plans to begin a randomized controlled trial (RCT) of Nana-val in the second half of 2025.

Posted In: VIRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist